On Dec. 12, 2020, AstraZeneca and Alexion Pharmaceuticals announced an agreement for AstraZeneca to acquire Alexion.

Alexion shareholders received $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) for each Alexion share. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39 billion or $175 per share.